1
|
Deuse T, Wang D, Stubbendorff M, Itagaki R, Grabosch A, Greaves LC, Alawi M, Grünewald A, Hu X, Hua X, Velden J, Reichenspurner H, Robbins RC, Jaenisch R, Weissman IL, Schrepfer S. SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts. Cell Stem Cell 2014; 16:33-8. [PMID: 25465116 DOI: 10.1016/j.stem.2014.11.003] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2014] [Revised: 09/27/2014] [Accepted: 11/07/2014] [Indexed: 12/26/2022]
Abstract
The generation of pluripotent stem cells by somatic cell nuclear transfer (SCNT) has recently been achieved in human cells and sparked new interest in this technology. The authors reporting this methodical breakthrough speculated that SCNT would allow the creation of patient-matched embryonic stem cells, even in patients with hereditary mitochondrial diseases. However, herein we show that mismatched mitochondria in nuclear-transfer-derived embryonic stem cells (NT-ESCs) possess alloantigenicity and are subject to immune rejection. In a murine transplantation setup, we demonstrate that allogeneic mitochondria in NT-ESCs, which are nucleus-identical to the recipient, may trigger an adaptive alloimmune response that impairs the survival of NT-ESC grafts. The immune response is adaptive, directed against mitochondrial content, and amenable for tolerance induction. Mitochondrial alloantigenicity should therefore be considered when developing therapeutic SCNT-based strategies.
Collapse
Affiliation(s)
- Tobias Deuse
- TSI Laboratory, University Heart Center Hamburg, Martinistrasse 52, 20246 Hamburg, Germany; Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany; Cardiovascular Surgery, University Heart Center Hamburg, Martinistrasse 52, 20246 Hamburg, Germany
| | - Dong Wang
- TSI Laboratory, University Heart Center Hamburg, Martinistrasse 52, 20246 Hamburg, Germany; Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany
| | - Mandy Stubbendorff
- TSI Laboratory, University Heart Center Hamburg, Martinistrasse 52, 20246 Hamburg, Germany; Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany
| | - Ryo Itagaki
- TSI Laboratory, University Heart Center Hamburg, Martinistrasse 52, 20246 Hamburg, Germany; Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany
| | - Antje Grabosch
- TSI Laboratory, University Heart Center Hamburg, Martinistrasse 52, 20246 Hamburg, Germany; Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany
| | - Laura C Greaves
- Newcastle University Centre for Brain Ageing and Vitality, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
| | - Malik Alawi
- Bioinformatics Service Facility, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany; Heinrich-Pette Institute, Leibniz Institute for Experimental Virology, Virus Genomics, Martinistrasse 52, 20246 Hamburg, Germany
| | - Anne Grünewald
- Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
| | - Xiaomeng Hu
- TSI Laboratory, University Heart Center Hamburg, Martinistrasse 52, 20246 Hamburg, Germany; Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany
| | - Xiaoqin Hua
- TSI Laboratory, University Heart Center Hamburg, Martinistrasse 52, 20246 Hamburg, Germany; Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany
| | - Joachim Velden
- Department of Nephropathology, Institute of Pathology, University Hospital Erlangen, Maximiliansplatz 2, 91054 Erlangen, Germany
| | - Hermann Reichenspurner
- Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany; Cardiovascular Surgery, University Heart Center Hamburg, Martinistrasse 52, 20246 Hamburg, Germany
| | - Robert C Robbins
- Stanford Cardiovascular Institute and Department of Cardiothoracic Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA
| | - Rudolf Jaenisch
- Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, 9 Cambridge Center, Cambridge, MA 02142, USA
| | - Irving L Weissman
- Department of Developmental Biology, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA
| | - Sonja Schrepfer
- TSI Laboratory, University Heart Center Hamburg, Martinistrasse 52, 20246 Hamburg, Germany; Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Martinistrasse 52, 20246 Hamburg, Germany; Stanford Cardiovascular Institute and Department of Cardiothoracic Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA.
| |
Collapse
|
6
|
Wettstein PJ. Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. II. Observation of a hierarchy among dominant antigens. Immunogenetics 1986; 24:24-31. [PMID: 2426194 DOI: 10.1007/bf00372294] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Immunization of C57BL/6 mice with BALB.B spleen cells in vivo and subsequent boosting in mixed lymphocyte culture result in the generation of cytolytic T lymphocytes (CTLs) which are specific for a limited number of immunodominant antigens. Experiments are described which suggest the existence of a hierarchy of immunodominance in this donor: host combination. Two antigens, CTT-1.3 and CTT-2.3, are dominant in the C57BL/6 anti-BALB.B CTL response. The distribution of these antigens among CXB recombinant inbred (RI) strains suggests that they segregate as single gene traits. Elimination of the CTT-1.3 and CTT-2.3 antigens by complementation in the responder, or elimination from the priming and boosting stages by the selection of CXB RI strain mice as responders or stimulators, reveals a second level of immunodominant antigens which include CTT-3.3 and CTT-4.3. CXB mice which express one of the CTT-1.3 or CTT-2.3 antigens will produce CTLs specific for the other antigen upon priming and boosting with BALB.B cells. Expression of both antigens in responders results in the generation of CTLs specific for the second level, dominant antigens. Immunodominance is not confined to the C57BL/6 anti-BALB.B system but can also be observed in the BALB.B anti-C57BL/6 and B10.D2 anti-DBA/2 systems. Finally, generation of CTLs following priming and boosting with dominant and dominated antigens presented on different cells confirmed that immunodominance can only be observed when the dominant and dominated antigens are presented on the same cells. These observations suggest that immunodominance is revealed at the level of antigen-presenting cells primarily involved in vivo priming.
Collapse
|
8
|
Halle-Pannenko O, Pritchard LL, Bruley-Rosset M, Berumen L, Motta R. Parameters involved in the induction and abrogation of the lethal graft-versus-host reaction directed against non-H-2 antigens. Immunol Rev 1985; 88:59-85. [PMID: 2417936 DOI: 10.1111/j.1600-065x.1985.tb01153.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The grafting of cells from donors incompatible for non-H-2 antigens alone can lead to GvHR mortality in up to 100% of lethally irradiated adult recipients. GvHR severity correlates with the number of mature immunocompetent cells present in the bone marrow inoculum. Histologic and clinical manifestations of GvHR observed in these mice differ from those seen when GvHR is induced across an H-2 barrier. The number of non-H-2 genes capable of influencing GvHR mortality is probably great, and their effects may vary as a function of sex. The non-H-2 genes influence GvHR mortality mainly via their interactions, the consequences of which are complex and can result in either cumulative or suppressive effects. GvHR mortality is considerably reduced by donor immunization, shortly before grafting, against host-specific non-H-2 antigens; and it is virtually abrogated by an additional immunization of the donors against nonspecific (foreign) H-2 antigens. Three weeks after grafting, these "protected" mice are easily distinguishable from those undergoing lethal GvHR, as assessed by both clinical appearance and histologic examination; in contrast, they are nearly indistinguishable from control mice grafted with syngeneic cells. However, depending upon the conditions used for the immunization, an additional immunization against nonspecific H-2 antigens can lead to acceleration rather than suppression of GvHR mortality; this phenomenon is not seen, under the same experimental conditions, after immunization against specific non-H-2 antigens alone. It is therefore suggested that a "second signal" provided by an additional nonspecific stimulus can potentiate either the establishment of specific suppression or the activation of a secondary ("positive") response. Suppressive effects of the specific and nonspecific immunizations are cumulative, and both treatments activate suppressor cells. The intensity of suppression induced by both specific and nonspecific immunizations is antigen dose-dependent. At equivalent antigen doses the specific immunization is considerably more effective than the nonspecific immunization, and is detectable after injection of as few as 2.5 X 10(5) cells. In both cases, irradiation of the immunizing cells abolishes the suppression induced by the lower cell doses tested, while it merely decreases the intensity of the suppression induced by the higher cell doses tested. The impairment of suppression after irradiation of the immunizing cells is not attributable to a modification of their homing pattern, but to the fact that proliferation of the immunizing cells, which leads to an augmentation of the antigen dose, is abolished by irradiation.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
|
10
|
Berumen L, Halle-Pannenko O, Festenstein H. Strong histocompatibility and cell-mediated cytotoxic effects of a single Mls difference demonstrated using a new congenic mouse strain. Eur J Immunol 1983; 13:292-300. [PMID: 6221931 DOI: 10.1002/eji.1830130405] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
In vivo and in vitro effects of incompatibility at the Mls locus have been studied utilizing a recently created congenic mouse strain. Results obtained with skin grafts were compared to those obtained in the mixed lymphocyte reaction (MLR) and cell-mediated cytotoxicity assays. The in vitro responsiveness of cells from skin-grafted mice was compared to that of cells from corresponding ungrafted mice. The results showed that: (a) Mlsa, strongly stimulatory in primary MLR, has a weak effect on skin graft rejection; specific in vivo preimmunization against Mlsa increases and accelerates the rejection of skin grafts, but abrogates the responsiveness in MLR; and (b) incompatibility for Mlsb, nonstimulatory in primary MLR, induces relatively rapid rejection of 100% of skin grafts; this rejection is dramatically accelerated by specific in vivo preimmunization and is followed by activation of helper and cytotoxic cells. Results obtained in the cell-mediated cytotoxicity assay suggest that the recognition of Mlsb determinants is H-2-restricted. Finally, the rejection of skin grafts incompatible for numerous non-H-2 loci is delayed by an additional incompatibility for Mlsb, suggesting that Mlsb decreases the response to other non-H-2 antigens, thus acting as a suppressor and/or competitor antigen. We conclude that, in contrast with previous findings, Mls incompatibility may have a strong effect on skin graft rejection, depending on the allelic combination involved, and, after in vivo immunization, Mlsb activates cell-mediated proliferative and cytotoxic responses and definitely is not "silent". The importance of the histocompatibility effects of Mls determinants and the variety of its biological functions are much in favor of the existence of a polymorphic and complex system capable of activating different cell subsets.
Collapse
|